Working with rabbits afflicted with familial hypercholesterolemia, a metabolic disorder, Wilson is trying to transfer good genes into defective hepatocytes, cells in the liver that .
They are a classic sign of severe familial hypercholesterolemia (FH), a genetic defect that leads to a tremendous buildup of cholesterol in the blood.
People with this condition, called familial hypercholesterolemia (FH), have 25 times the normal risk of heart disease.
Esperion Therapeutics, Inc. Announces Pricing of Initial Public Offering Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.
June 26, 2013 - Business Wire via Yahoo! Finance
Low-income uninsured U.S. adults less likely to have chronic conditions compared with medicaid enrollees Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a new study.
June 23, 2013 - Science Daily